TSZY(SZ:002872) Xin Lang Cai Jing·2025-09-25 10:04Core Viewpoint - Tian Sheng Pharmaceutical Group held an investor relations meeting to address various inquiries regarding its performance and future strategies, focusing on governance, sales expenses, share repurchase, and innovation in drug development [1][2][3][4] Group 1: Governance and Risk Warning - Tian Sheng Pharmaceutical's stock was placed under risk warning due to fund misappropriation by its controlling shareholder, with the company having repaid the principal and interest by April 2021. However, it received a notice of administrative penalty from the Chongqing Securities Regulatory Bureau in September 2025, leading to continued risk warnings [1] - The company is committed to enhancing corporate governance and internal control management to meet the conditions for lifting the risk warning [1] Group 2: Sales Strategy - As a pharmaceutical manufacturer, Tian Sheng Pharmaceutical incurs high sales expenses, exceeding 20% of revenue, due to the need to establish nationwide sales channels and adapt sales strategies to expand market reach [2] Group 3: Share Repurchase and Market Value Management - The company plans to utilize its own funds or special loans for share repurchase to enhance investor confidence and maintain market value, ensuring compliance with legal requirements and committing to timely information disclosure [3] Group 4: Innovation and Export - Tian Sheng Pharmaceutical has over 300 approved drug varieties, covering multiple therapeutic areas, and is focused on continuous research and development, production excellence, and sales expansion to achieve sustainable growth and turnaround from losses [4] - Currently, the company does not engage in drug exports but emphasizes strict adherence to quality control regulations [4]